Lenire Tinnitus Treatment Included in US Otolaryngology Guidelines
Lenire, a treatment for tinnitus, has been added to the clinical practice guidelines of the American Academy of Otolaryngology. It is the first new treatment method recommended since the guidelines' initial release.
The American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNS) has included Lenire (bimodal neuromodulation) as a treatment option in its clinical practice guidelines for tinnitus. This inclusion marks a significant recognition of Lenire as a potential therapeutic approach.
Lenire is the sole new treatment recommendation incorporated into the AAO-HNS tinnitus guidelines since their original publication. This development follows Lenire's prior clearance from the FDA for treating tinnitus through bilateral neuromodulation, which involves stimulation of both the oral cavity and the vagus nerve.
Tinnitus, often experienced as a ringing or buzzing sound in the ears, can significantly impair a person's quality of life. The update to the AAO-HNS guidelines reflects an ongoing effort to integrate the latest scientific evidence and treatment modalities into clinical practice.
The inclusion in the guidelines may influence the adoption and utilization of Lenire within the US healthcare system, offering clinicians another option to consider for patients who have not found relief through conventional therapies.